NCT01489371View on ClinicalTrials.gov

EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

July 9, 2012

Primary Completion Date

December 30, 2014

Study Completion Date

January 27, 2018

Conditions
Ovarian Clear Cell CystadenocarcinomaOvarian Endometrioid AdenocarcinomaOvarian Seromucinous CarcinomaOvarian Serous CystadenocarcinomaOvarian Undifferentiated CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal Carcinoma
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

PEG-PEI-cholesterol Lipopolymer-encased IL-12 DNA Plasmid Vector GEN-1

Given IP

DRUG

Pegylated Liposomal Doxorubicin Hydrochloride

Given IV

Trial Locations (7)

35233

University of Alabama at Birmingham Cancer Center, Birmingham

44106

Case Western Reserve University, Cleveland

53226

Froedtert and the Medical College of Wisconsin, Milwaukee

63110

Washington University School of Medicine, St Louis

73104

University of Oklahoma Health Sciences Center, Oklahoma City

87102

University of New Mexico Cancer Center, Albuquerque

92868

UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Gynecologic Oncology Group

NETWORK

NCT01489371 - EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | Biotech Hunter | Biotech Hunter